Back to results
US 2022/0267260 A1Published application
Compounds containing a sulfonic group as kat inhibitors
AssigneeEpizyme, Inc.
InventorDarren Martin Harvey
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Claims24
A compound of formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- Ring A is selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic aryl ring, an 8-10 membered bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur;
- L is a 3- to 6-atom linker comprising at least one —S(O)2— group and 1-4 additional groups independently selected from —C(O)—, —NH—, —O—, and C1-3 aliphatic;
- wherein:
- two atoms of L may, together with their intervening atoms, form a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, or a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur;
- Ring B is an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic aryl ring, and an 8-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur;
- Ra is selected from halogen, —CN, —NO2, —OR, —SR, —N(R)2, —C(O)R, —C(O)2R, —OC(O)R, —C(O)N(R)2, —N(R)C(O)R, —Cy, or optionally substituted C1-4 aliphatic;
- Z is selected from halogen, —CN, —NO2, —OR, —SR, —N(R)2, —C(O)R, —C(O)2R, —OC(O)R, —C(O)N(R)2, —N(R)C(O)R, —Cy, —(C1-3 aliphatic)-Cy or optionally substituted C1-4 aliphatic;
- Cy is an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 6-8 membered bridged bicyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic aryl ring, and an 8-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur;
- each R is independently hydrogen or an optionally substituted group selected from C1-4 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic aryl ring, and an 8-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur;
- n is 0 or 1;
- and
- x is 0, 1, 2, or 3.
10 more elements
(canceled)
(canceled)
12-14. (canceled)
16-22. (canceled)
Dependencies are inferred from the claim text.